Positive impact of blocking tumor necrosis factor α on the nutritional status in pediatric Crohn's disease patients

International Journal of Colorectal Disease

Volumn 24, Issue 1, 2009, Pages 19-25

  Diamanti, A ^a   Basso, M S ^a   Gambarara, M ^a   Papadatou, B ^a   Bracci, F ^a   Noto, C ^a   Castro, M ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Children; Crohn's disease; Humans; Infliximab; Nutritional status; TNF

Indexed keywords

AMPHOTERICIN B; AZATHIOPRINE; INFLIXIMAB; MESALAZINE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ANAPHYLAXIS; ARTHRALGIA; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; ENERGY EXPENDITURE; FEMALE; FLUSHING; FOOD INTAKE; HEART FUNCTION; HEIGHT; HUMAN; HYPOTENSION; MALE; MYALGIA; MYCOSIS; NUTRITIONAL STATUS; PRIORITY JOURNAL; RESPIRATORY FUNCTION; SCHOOL CHILD; SEPTICEMIA; SIDE EFFECT; TACHYCARDIA; THORAX PAIN; TREATMENT DURATION; URTICARIA; WEIGHT;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; BODY HEIGHT; BODY MASS INDEX; BODY WEIGHT; CASE-CONTROL STUDIES; CHILD; CROHN DISEASE; EATING; ENERGY METABOLISM; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MESALAMINE; NUTRITIONAL STATUS; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 57049182553     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-008-0578-x     Document Type: Article

References (38)

1. Cezard JP, Touati G, Alberti C et al (2002) Growth in pediatric Crohn's disease. Horm Res 58:11-15
2. Savage MO, Beattie RM, Camacho-Hubner C et al (1999) Growth in Crohn's disease. Acta Paediatrica 88:89-92
3. Griffiths AM, Phoungbich N, Smith C et al (1993) Growth and clinical course of children with Crohn's disease. Gut 34:939-943
4. Newby EA, Sawczenko A, Thomas AG, Wilson D (2005) Interventions for growth failure in childhood Crohn's disease. Cochrane Database Syst Rev 20(3):CD003873
5. Walters TD, Gilman AR, Griffiths AM (2007) Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis 13(4):424-430
6. Söderholm JD, Streutker C, Yang PC et al (2004) Increased epithelial uptake of protein antigens in the ileum of Crohn's disease mediated by tumor necrosis factor α. Gut 53:1817-1824
7. Gibson PR (2004) Increased gut permeability in Crohn's disease: Is TNF the link. Gut 53:1724-1725
8. Yan F, John SK, Wilson G et al (2004) Kinase suppressor of Ras-1 protects intestinal epithelium from cytokine-mediated apoptosis during inflammation. J Clin Invest 114(9):1272-1280
9. Escher JC, Taminiau JAJM, Nieuwenhuis EES et al (2003) Treatment of inflammatory bowel disease in childhood: Best available evidence. Inflamm Bowel Dis 9:34-58
10. Kleinman RE, Baldassano RN, Caplan A et al (2004) Nutrition support for pediatric patients with inflammatory bowel disease: A clinical report of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 39:15-27
11. Manolagas SC, Jilka RL (1995) Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332:305-311
12. Baldassano R, Braegger CP, Escher JC et al (2003) Infliximab therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 98:833-838
13. Borrelli O, Bascietto C, Viola F et al (2004) Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 36:342-347
14. Tynjala P, Lahdenne P, Vahasalo P et al (2006) Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis. Ann Rheum Dis 65:1044-1049
15. Hyams J, Crandall W, Kugathasan S et al (2007) Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 132(3):863-873
16. Franchimont D, Roland S, Gustot T et al (2005) Impact of infliximab on serum leptin levels in patients with Crohn's disease. J Clin Endocrinol Metab 90:3510-3516
17. NASPGHAN (2007) Differentiating ulcerative colitis from Crohn disease in children and young adults: Report of a working group of the NASPGHAN and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 44:653-674
18. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (2005) Inflammatory bowel disease in children and adolescents: Recommendations for diagnosis - the Porto criteria. J Pediatr Gastroenterol Nutr 41(1):1-7
19. Hyams JS, Ferry GD, Mandel FS et al (1991) Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 12:439-447
20. Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) ACCENT I Study Group. Maintenance infliximab for Crohn's disease: The ACCENT 1 randomised trial. Lancet 342:174-175
21. Levine A, Broide E, Stein M et al (2002) Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease. J Pediatr 140:75-80
22. Schofield W (1985) Predicting basal metabolic rate, new standards and review of previous work. Hum Nutr Clin Nutr 39:5-41
23. Food and Nutrition Board, National Research Council (1989) Recommended Dietary Allowances, 10th edn. National Academy Press, Washington, DC
24. Kundhal P, Zachos M, Holmes JL, Griffiths AM (2001) Controlled ileal release budesonide in pediatric Crohn's disease: Efficacy and effects on growth. J Pediatr Gatroenterol Nutr 33:75-80
25. Markowitz J, Grancher K, Kohn N et al (2000) A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 119:895-902
26. Berni Canani R, Terrin G, Borrelli O et al (2006) Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease. Dig Liver Dis 38(6):381-387
27. Cezard JP, Nouaili N, Talbotec C et al (2003) A prospective study of the efficacy and tolerance of chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn's disease. J Pediatr Gatroenterol Nutr 36:632-636
28. deRidder L, Escher J, Bouquet J et al (2004) Infliximab therapy in 30 patients with refractory pediatric Crohn disease with and without fistulas in The Netherlands. J Pediatr Gatroenterol Nutr 39:46-52
29. Ballinger A (2002) Fundamental mechanisms of growth failure in inflammatory bowel disease. Horm Res 58:7-10
30. Hart JW, Bremner AR, Wootton SA, Beattie RM (2005) Measured versus predicted energy expenditure in children with inactive Crohn's disease. Clin Nutr 24:1047-1055
31. Azcue M, Rashid M, Griffiths A, Pencharz PB (1997) Energy expenditure and body composition in children with Crohn's disease: Effect of enteral nutrition and treatment with prednisolone. Gut 41:203-208
32. Varille V, Cezard JP, de Lagausie P, Bellaiche M et al (1996) Resting energy expenditure before and after gut resection of gut lesions in pediatric Crohn's disease. J Pediatr Gatroenterol Nutr 9:13-9
33. Kushner RF, Schoeller DA (1991) Resting energy expenditure in patients with inflammatory bowel disease. Am J Clin Nutr 53:161-165
34. Andrassy RJ, Chwals WJ (1998) Nutritional support of the pediatric oncology patient. Nutrition 14:124-129
35. Cole TJ (2004) Children grow and horses race: Is the adiposity rebound a critical period for later obesity. BMC Pediatrics 4:6-12
36. Segal KR, Burastero S, Chun A et al (1991) Estimation of extracellular and total body water by multiple-frequency bioelectrical-impedance measurement. Am J Clin Nutr 54:26-29
37. Rosenbaum M, Leibel RL, Hirsch J (1997) Obesity. N Engl J Med 337:396-407
38. Gordon CM, Goodman E, Emans SJ et al (2002) Physiologic regulators of bone turnover in young women with anorexia nervosa. J Pediatr 141:64-70